{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:46:59Z","timestamp":1791316019694,"version":"4.3.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T00:00:00Z","timestamp":1439856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acamprosate has been widely used since the Food and Drug Administration approved the medication for treatment of alcohol use disorders (AUDs) in 2004. Although the detailed molecular mechanism of acamprosate remains unclear, it has been largely known that acamprosate inhibits glutamate action in the brain. However, AUD is a complex and heterogeneous disorder. Thus, biomarkers are required to prescribe this medication to patients who will have the highest likelihood of responding positively. To identify pharmacometabolomic biomarkers of acamprosate response, we utilized serum samples from 120 alcohol-dependent subjects, including 71 responders (maintained continuous abstinence) and 49 non-responders (any alcohol use) during 12 weeks of acamprosate treatment. Notably, baseline serum glutamate levels were significantly higher in responders compared with non-responders. Importantly, serum glutamate levels of responders are normalized after acamprosate treatment, whereas there was no significant glutamate change in non-responders. Subsequent functional studies in animal models revealed that, in the absence of alcohol, acamprosate activates glutamine synthetase, which synthesizes glutamine from glutamate and ammonia. These results suggest that acamprosate reduces serum glutamate levels for those who have elevated baseline serum glutamate levels among responders. Taken together, our findings demonstrate that elevated baseline serum glutamate levels are a potential biomarker associated with positive acamprosate response, which is an important step towards development of a personalized approach to treatment for AUD.<\/jats:p>","DOI":"10.1038\/tp.2015.120","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T13:43:06Z","timestamp":1439905386000},"page":"e621-e621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects"],"prefix":"10.1038","volume":"5","author":[{"given":"H W","family":"Nam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V M","family":"Karpyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Hinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J R","family":"Geske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M C","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M L","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Biernacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Frye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R M","family":"Weinshilboum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D-S","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,18]]},"reference":[{"key":"BFtp2015120_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(02)11403-6","volume":"360","author":"M Ezzati","year":"2002","unstructured":"Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ . Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347\u20131360.","journal-title":"Lancet"},{"key":"BFtp2015120_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1001\/archpsyc.1984.01790210031005","volume":"41","author":"LN Robins","year":"1984","unstructured":"Robins LN, Helzer JE, Weissman MM, Orvaschel H, Gruenberg E, Burke JD Jr. et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949\u2013958.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2015120_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/475027a","volume":"475","author":"PY Collins","year":"2011","unstructured":"Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS et al. Grand challenges in global mental health. Nature 2011; 475: 27\u201330.","journal-title":"Nature"},{"key":"BFtp2015120_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/npp.2009.110","volume":"35","author":"GF Koob","year":"2010","unstructured":"Koob GF, Volkow ND . Neurocircuitry of addiction. Neuropsychopharmacology 2010; 35: 217\u2013238.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015120_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.15288\/jsa.1987.48.356","volume":"48","author":"BI Liskow","year":"1987","unstructured":"Liskow BI, Goodwin DW . Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. J Stud Alcohol 1987; 48: 356\u2013370.","journal-title":"J Stud Alcohol"},{"key":"BFtp2015120_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1146\/annurev.med.49.1.173","volume":"49","author":"G Tsai","year":"1998","unstructured":"Tsai G, Coyle JT . The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998; 49: 173\u2013184.","journal-title":"Annu Rev Med"},{"key":"BFtp2015120_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/S0301-0082(99)00031-3","volume":"60","author":"A Dahchour","year":"2000","unstructured":"Dahchour A, De Witte P . Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate. Prog Neurobiol 2000; 60: 343\u2013362.","journal-title":"Prog Neurobiol"},{"key":"BFtp2015120_CR8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1530-0277.2002.tb02578.x","volume":"26","author":"GF Koob","year":"2002","unstructured":"Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR . Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res 2002; 26: 586\u2013592.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFtp2015120_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/archgenpsychiatry.2010.125","volume":"67","author":"JC Umhau","year":"2010","unstructured":"Umhau JC, Momenan R, Schwandt ML, Singley E, Lifshitz M, Doty L et al. Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study. Arch Gen Psychiatry 2010; 67: 1069\u20131077.","journal-title":"Arch Gen Psychiatry"},{"key":"BFtp2015120_CR10","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1016\/j.neuropharm.2012.02.022","volume":"62","author":"DJ Hinton","year":"2012","unstructured":"Hinton DJ, Lee MR, Jacobson TL, Mishra PK, Frye MA, Mrazek DA et al. Ethanol withdrawal-induced brain metabolites and the pharmacological effects of acamprosate in mice lacking ENT1. Neuropharmacology 2012; 62: 2480\u20132488.","journal-title":"Neuropharmacology"},{"key":"BFtp2015120_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","volume":"28","author":"K Mann","year":"2004","unstructured":"Mann K, Lehert P, Morgan MY . The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28: 51\u201363.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFtp2015120_CR12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1001\/jama.2014.3628","volume":"311","author":"DE Jonas","year":"2014","unstructured":"Jonas DE, Amick HR, Feltner C, Bobashev G, Thomas K, Wines R et al. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA 2014; 311: 1889\u20131900.","journal-title":"JAMA"},{"key":"BFtp2015120_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0269881107078308","volume":"22","author":"S Rosner","year":"2008","unstructured":"Rosner S, Leucht S, Lehert P, Soyka M . Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22: 11\u201323.","journal-title":"J Psychopharmacol"},{"key":"BFtp2015120_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/adb.12012","volume":"18","author":"K Mann","year":"2013","unstructured":"Mann K, Lemenager T, Hoffmann S, Reinhard I, Hermann D, Batra A et al. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. Addict Biol 2013; 18: 937\u2013946.","journal-title":"Addict Biol"},{"key":"BFtp2015120_CR15","doi-asserted-by":"publisher","first-page":"14187","DOI":"10.1073\/pnas.0907721106","volume":"106","author":"ID Wilson","year":"2009","unstructured":"Wilson ID . Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring. Proc Natl Acad Sci USA 2009; 106: 14187\u201314188.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFtp2015120_CR16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/187152710790966641","volume":"9","author":"BJ Mason","year":"2010","unstructured":"Mason BJ, Heyser CJ . Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 2010; 9: 23\u201332.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"BFtp2015120_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/npp.2013.181","volume":"39","author":"SE Hyman","year":"2014","unstructured":"Hyman SE . Revitalizing psychiatric therapeutics. Neuropsychopharmacology 2014; 39: 220\u2013229.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015120_CR18","doi-asserted-by":"publisher","first-page":"220ps1","DOI":"10.1126\/scitranslmed.3005237","volume":"6","author":"TJ Urban","year":"2014","unstructured":"Urban TJ, Goldstein DB . Pharmacogenetics at 50: genomic personalization comes of age. Sci Transl Med 2014; 6: 220ps1.","journal-title":"Sci Transl Med"},{"key":"BFtp2015120_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/clpt.2013.217","volume":"95","author":"R Kaddurah-Daouk","year":"2014","unstructured":"Kaddurah-Daouk R, Weinshilboum RM . Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology. Clin Pharmacol Ther 2014; 95: 154\u2013167.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtp2015120_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/clpt.2013.166","volume":"94","author":"LP James","year":"2013","unstructured":"James LP . Metabolomics: integration of a new \"omics\" with clinical pharmacology. Clin Pharmacol Ther 2013; 94: 547\u2013551.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtp2015120_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/npp.2013.210","volume":"39","author":"KJ Bough","year":"2014","unstructured":"Bough KJ, Amur S, Lao G, Hemby SE, Tannu NS, Kampman KM et al. Biomarkers for the development of new medications for cocaine dependence. Neuropsychopharmacology 2014; 39: 202\u2013219.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015120_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/cpt.134","volume":"98","author":"R Kaddurah-Daouk","year":"2015","unstructured":"Kaddurah-Daouk R, Weinshilboum R . Metabolomic signatures for drug response phenotypes-pharmacometabolomics enables precision medicine. Clin Pharmacol Ther 2015; 98: 71\u201375.","journal-title":"Clin Pharmacol Ther"},{"key":"BFtp2015120_CR23","doi-asserted-by":"publisher","first-page":"e68283","DOI":"10.1371\/journal.pone.0068283","volume":"8","author":"H Zhu","year":"2013","unstructured":"Zhu H, Bogdanov MB, Boyle SH, Matson W, Sharma S, Matson S et al. Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway. PLoS One 2013; 8: e68283.","journal-title":"PLoS One"},{"key":"BFtp2015120_CR24","doi-asserted-by":"crossref","unstructured":"Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 2011; 1: e26.","DOI":"10.1038\/tp.2011.22"},{"key":"BFtp2015120_CR25","doi-asserted-by":"publisher","first-page":"e42165","DOI":"10.1371\/journal.pone.0042165","volume":"7","author":"JK Yao","year":"2012","unstructured":"Yao JK, Condray R, Dougherty GG Jr., Keshavan MS, Montrose DM, Matson WR et al. Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS One 2012; 7: e42165.","journal-title":"PLoS One"},{"key":"BFtp2015120_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1017\/S1461145710001689","volume":"14","author":"R Condray","year":"2011","unstructured":"Condray R, Dougherty GG Jr., Keshavan MS, Reddy RD, Haas GL, Montrose DM et al. 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011; 14: 756\u2013767.","journal-title":"Int J Neuropsychopharmacol"},{"key":"BFtp2015120_CR27","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1111\/bph.12494","volume":"171","author":"A Villasenor","year":"2014","unstructured":"Villasenor A, Ramamoorthy A, Silva dos Santos M, Lorenzo MP, Laje G, Zarate C Jr. et al. A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response-related difference in mitochondrial networks. Br J Pharmacol 2014; 171: 2230\u20132242.","journal-title":"Br J Pharmacol"},{"key":"BFtp2015120_CR28","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1038\/tp.2014.103","volume":"4","author":"VM Karpyak","year":"2014","unstructured":"Karpyak VM, Biernacka JM, Geske JR, Jenkins GD, Cunningham JM, Ruegg J et al. Genetic markers associated with abstinence length in alcohol-dependent subjects treated with acamprosate. Transl Psychiatry 2014; 4: e453.","journal-title":"Transl Psychiatry"},{"key":"BFtp2015120_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/JCP.0000000000000075","volume":"34","author":"D Hasin","year":"1998","unstructured":"Hasin D, Trautman K, Endicott J . Psychiatric research interview for substance and mental disorders: phenomenologically based diagnosis in patients who abuse alcohol or drugs. Psychopharmacol Bull 1998; 34: 3\u20138.","journal-title":"Psychopharmacol Bull"},{"key":"BFtp2015120_CR30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","volume":"84","author":"JT Sullivan","year":"1989","unstructured":"Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM . Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84: 1353\u20131357.","journal-title":"Br J Addict"},{"key":"BFtp2015120_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.15288\/jsa.2003.64.858","volume":"64","author":"LC Sobell","year":"2003","unstructured":"Sobell LC, Agrawal S, Sobell MB, Leo GI, Young LJ, Cunningham JA et al. Comparison of a quick drinking screen with the timeline followback for individuals with alcohol problems. J Stud Alcohol 2003; 64: 858\u2013861.","journal-title":"J Stud Alcohol"},{"key":"BFtp2015120_CR32","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1021\/bi00846a016","volume":"7","author":"HS Kingdon","year":"1968","unstructured":"Kingdon HS, Hubbard JS, Stadtman ER . Regulation of glutamine synthetase. XI. The nature and implications of a lag phase in the Escherichia coli glutamine synthetase reaction. Biochemistry 1968; 7: 2136\u20132142.","journal-title":"Biochemistry"},{"key":"BFtp2015120_CR33","doi-asserted-by":"publisher","first-page":"e10538","DOI":"10.1371\/journal.pone.0010538","volume":"5","author":"IR Lanza","year":"2010","unstructured":"Lanza IR, Zhang S, Ward LE, Karakelides H, Raftery D, Nair KS . Quantitative metabolomics by H-NMR and LC-MS\/MS confirms altered metabolic pathways in diabetes. PLoS One 2010; 5: e10538.","journal-title":"PLoS One"},{"key":"BFtp2015120_CR34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nprot.2006.478","volume":"2","author":"C Frezza","year":"2007","unstructured":"Frezza C, Cipolat S, Scorrano L . Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2007; 2: 287\u2013295.","journal-title":"Nat Protoc"},{"key":"BFtp2015120_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","volume":"23","author":"BA Flannery","year":"1999","unstructured":"Flannery BA, Volpicelli JR, Pettinati HM . Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 1999; 23: 1289\u20131295.","journal-title":"Alcohol Clin Exp Res"},{"key":"BFtp2015120_CR36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.nurt.2010.05.015","volume":"7","author":"SW Brusilow","year":"2010","unstructured":"Brusilow SW, Koehler RC, Traystman RJ, Cooper AJ . Astrocyte glutamine synthetase: importance in hyperammonemic syndromes and potential target for therapy. Neurotherapeutics 2010; 7: 452\u2013470.","journal-title":"Neurotherapeutics"},{"key":"BFtp2015120_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0010-406X(63)90169-5","volume":"34","author":"C Wu","year":"1963","unstructured":"Wu C . Glutamine synthetase. I. A comparative study of its distribution in animals and its inhibition by Dl-allo-delta-hydroxylysine. Comp Biochem Physiol 1963; 34: 335\u2013351.","journal-title":"Comp Biochem Physiol"},{"key":"BFtp2015120_CR38","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.nbd.2009.02.019","volume":"35","author":"MP Quinones","year":"2009","unstructured":"Quinones MP, Kaddurah-Daouk R . Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiol Dis 2009; 35: 165\u2013176.","journal-title":"Neurobiol Dis"},{"key":"BFtp2015120_CR39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/npp.2013.167","volume":"39","author":"PL Wood","year":"2014","unstructured":"Wood PL . Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology. Neuropsychopharmacology 2014; 39: 24\u201333.","journal-title":"Neuropsychopharmacology"},{"key":"BFtp2015120_CR40","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/jcbfm.2013.186","volume":"34","author":"A Ruban","year":"2014","unstructured":"Ruban A, Mohar B, Jona G, Teichberg VI . Blood glutamate scavenging as a novel neuroprotective treatment for paraoxon intoxication. J Cereb Blood Flow Metab 2014; 34: 221\u2013227.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFtp2015120_CR41","doi-asserted-by":"publisher","first-page":"10041","DOI":"10.3390\/ijms130810041","volume":"13","author":"A Leibowitz","year":"2012","unstructured":"Leibowitz A, Boyko M, Shapira Y, Zlotnik A . Blood glutamate scavenging: insight into neuroprotection. Int J Mol Sci 2012; 13: 10041\u201310066.","journal-title":"Int J Mol Sci"},{"key":"BFtp2015120_CR42","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nm1163","volume":"11","author":"R Spanagel","year":"2005","unstructured":"Spanagel R, Pendyala G, Abarca C, Zghoul T, Sanchis-Segura C, Magnone MC et al. The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nat Med 2005; 11: 35\u201342.","journal-title":"Nat Med"},{"key":"BFtp2015120_CR43","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/jcbfm.2010.22","volume":"30","author":"A Goldbecker","year":"2010","unstructured":"Goldbecker A, Buchert R, Berding G, Bokemeyer M, Lichtinghagen R, Wilke F et al. Blood-brain barrier permeability for ammonia in patients with different grades of liver fibrosis is not different from healthy controls. J Cereb Blood Flow Metab 2010; 30: 1384\u20131393.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFtp2015120_CR44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/alcalc\/agp070","volume":"45","author":"M Kravos","year":"2010","unstructured":"Kravos M, Malesic I . Glutamate dehydrogenase as a marker of alcohol dependence. Alcohol Alcohol 2010; 45: 39\u201344.","journal-title":"Alcohol Alcohol"},{"key":"BFtp2015120_CR45","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW . Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction 2013; 108: 275\u2013293.","journal-title":"Addiction"},{"key":"BFtp2015120_CR46","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/sj.mp.4002000","volume":"12","author":"R Kaddurah-Daouk","year":"2007","unstructured":"Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM et al. Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007; 12: 934\u2013945.","journal-title":"Mol Psychiatry"},{"key":"BFtp2015120_CR47","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1146\/annurev.pharmtox.48.113006.094715","volume":"48","author":"R Kaddurah-Daouk","year":"2008","unstructured":"Kaddurah-Daouk R, Kristal BS, Weinshilboum RM . Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008; 48: 653\u2013683.","journal-title":"Annu Rev Pharmacol Toxicol"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp2015120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015120","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2015120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:52:29Z","timestamp":1672912349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp2015120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,18]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8]]}},"alternative-id":["BFtp2015120"],"URL":"https:\/\/doi.org\/10.1038\/tp.2015.120","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,18]]},"assertion":[{"value":"4 March 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The medication (acamprosate) used in this study was in part provided by Forest Pharmaceuticals. Other than providing medication, neither Forest Pharmaceuticals nor its affiliates were involved in study conceptualization, design, data collection, data analysis, interpretation or preparation of the manuscript. Dr MAF has had grant support from Pfizer and Myriad, and has served as an unpaid consultant for Allergan, Myriad, Sunovion and Teva Pharmaceuticals. The remaining authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}